Wells Fargo & Company Design Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 18,428 shares of DSGN stock, worth $75,186. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,428
Previous 14,415
27.84%
Holding current value
$75,186
Previous $77,000
46.75%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding DSGN
# of Institutions
100Shares Held
31.5MCall Options Held
2.3KPut Options Held
2.7K-
Sr One Capital Management, LP6.53MShares$26.6 Million14.99% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$17.2 Million3.42% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$9.4 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.89MShares$7.72 Million0.55% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.86MShares$7.58 Million0.03% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $228M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...